These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 23995279)

  • 21. Development of therapy for Duchenne muscular dystrophy.
    Zhang S; Xie H; Zhou G; Yang Z
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2007 Feb; 21(2):194-203. PubMed ID: 17357471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
    Aartsma-Rus A; Fokkema I; Verschuuren J; Ginjaar I; van Deutekom J; van Ommen GJ; den Dunnen JT
    Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of p38 signaling increases utrophin A expression in skeletal muscle via the RNA-binding protein KSRP and inhibition of AU-rich element-mediated mRNA decay: implications for novel DMD therapeutics.
    Amirouche A; Tadesse H; Lunde JA; Bélanger G; Côté J; Jasmin BJ
    Hum Mol Genet; 2013 Aug; 22(15):3093-111. PubMed ID: 23575223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.
    Béroud C; Tuffery-Giraud S; Matsuo M; Hamroun D; Humbertclaude V; Monnier N; Moizard MP; Voelckel MA; Calemard LM; Boisseau P; Blayau M; Philippe C; Cossée M; Pagès M; Rivier F; Danos O; Garcia L; Claustres M
    Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic therapeutic approaches for Duchenne muscular dystrophy.
    Foster H; Popplewell L; Dickson G
    Hum Gene Ther; 2012 Jul; 23(7):676-87. PubMed ID: 22647146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells.
    Aartsma-Rus A; Kaman WE; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC
    Gene Ther; 2004 Sep; 11(18):1391-8. PubMed ID: 15229633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Duchenne and Becker muscular dystrophies.
    Flanigan KM
    Neurol Clin; 2014 Aug; 32(3):671-88, viii. PubMed ID: 25037084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Muscle ERRγ mitigates Duchenne muscular dystrophy via metabolic and angiogenic reprogramming.
    Matsakas A; Yadav V; Lorca S; Narkar V
    FASEB J; 2013 Oct; 27(10):4004-16. PubMed ID: 23781095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of dystrophin expression by exon skipping in mdx mice following intramuscular injection of antisense oligonucleotides complexed with PEG-PEI copolymers.
    Williams JH; Sirsi SR; Latta DR; Lutz GJ
    Mol Ther; 2006 Jul; 14(1):88-96. PubMed ID: 16488666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Naturally occurring utrophin correlates with disease severity in Duchenne muscular dystrophy.
    Kleopa KA; Drousiotou A; Mavrikiou E; Ormiston A; Kyriakides T
    Hum Mol Genet; 2006 May; 15(10):1623-8. PubMed ID: 16595608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Skeletal muscle secretome in Duchenne muscular dystrophy: a pivotal anti-inflammatory role of adiponectin.
    Lecompte S; Abou-Samra M; Boursereau R; Noel L; Brichard SM
    Cell Mol Life Sci; 2017 Jul; 74(13):2487-2501. PubMed ID: 28188344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
    McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD
    Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches.
    Fairclough RJ; Wood MJ; Davies KE
    Nat Rev Genet; 2013 Jun; 14(6):373-8. PubMed ID: 23609411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Duchenne muscular dystrophy cell culture models created by CRISPR/Cas9 gene editing and their application in drug screening.
    Soblechero-Martín P; Albiasu-Arteta E; Anton-Martinez A; de la Puente-Ovejero L; Garcia-Jimenez I; González-Iglesias G; Larrañaga-Aiestaran I; López-Martínez A; Poyatos-García J; Ruiz-Del-Yerro E; Gonzalez F; Arechavala-Gomeza V
    Sci Rep; 2021 Sep; 11(1):18188. PubMed ID: 34521928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toward an oligonucleotide therapy for Duchenne muscular dystrophy: a complex development challenge.
    Wood MJ
    Sci Transl Med; 2010 Mar; 2(25):25ps15. PubMed ID: 20424011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors.
    Miyatake S; Shimizu-Motohashi Y; Takeda S; Aoki Y
    Drug Des Devel Ther; 2016; 10():2745-58. PubMed ID: 27621596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Duchenne and Becker Muscular Dystrophies: A Review of Animal Models, Clinical End Points, and Biomarker Quantification.
    Wilson K; Faelan C; Patterson-Kane JC; Rudmann DG; Moore SA; Frank D; Charleston J; Tinsley J; Young GD; Milici AJ
    Toxicol Pathol; 2017 Oct; 45(7):961-976. PubMed ID: 28974147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular, cellular, and pharmacological therapies for Duchenne/Becker muscular dystrophies.
    Chakkalakal JV; Thompson J; Parks RJ; Jasmin BJ
    FASEB J; 2005 Jun; 19(8):880-91. PubMed ID: 15923398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eteplirsen in the treatment of Duchenne muscular dystrophy.
    Lim KR; Maruyama R; Yokota T
    Drug Des Devel Ther; 2017; 11():533-545. PubMed ID: 28280301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological TRPC6 inhibition improves survival and muscle function in mice with Duchenne muscular dystrophy.
    Lin BL; Shin JY; Jeffreys WP; Wang N; Lukban CA; Moorer MC; Velarde E; Hanselman OA; Kwon S; Kannan S; Riddle RC; Ward CW; Pullen SS; Filareto A; Kass DA
    JCI Insight; 2022 Oct; 7(19):. PubMed ID: 36099033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.